Enhanced recruitment and hematopoietic reconstitution of bone marrow‐derived mesenchymal stem cells in bone marrow failure by the SDF‐1/CXCR4
- 6 July 2020
- journal article
- research article
- Published by Wiley in Journal of Tissue Engineering and Regenerative Medicine
- Vol. 14 (9) , 1250-1260
Abstract
Aplastic anemia (AA) is a bone marrow failure disease. It is difficult to treat AA, and in addition, relapses are common because of its complex disease pathogenesis. Allogeneic bone marrow‐derived mesenchymal stem cells (BMSCs) infusion is an effective and safe treatment option for the AA patients. However, it found that BMSCs infusion in AA patients is less than 30% effective. Therefore, the key to improve the efficacy of BMSCs treatment in these patients is to enhance their homing efficiency to the target sites. Studies have shown that stromal cell‐derived factor‐1 (SDF‐1)/CXC chemokine receptor 4 (CXCR4) axis plays an important role in promoting BMSCs homing. In this study, human BMSCs were transduced with lentivirus stably expressing CXCR4‐BMSCs. Transduced BMSCs resemble normal BMSCs in many ways. Migration ability of CXCR4‐BMSCs toward SDF‐1 was increased because of the overexpression of CXCR4. In the mice with bone marrow failure, the migration and colonization ability of CXCR4‐BMSCs to the bone marrow was significantly improved as seen by IVIS imaging and FACS. The SDF‐1 level in the bone marrow failure mice was significantly higher than in the normal mice. Thus, from our study, it is clear that after CXCR4‐BMSCs were infused into mice with bone marrow failure, SDF‐1 interacted with CXCR4 receptor, leading cells to migrate and colonize to bone marrow. Because of the high SDF‐1 expression in mouse bone marrow and CXCR4 receptor expression in cells, BMSCs homing was increased.Keywords
This publication has 33 references indexed in Scilit:
- Efficacy and safety of mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemiaCytotherapy, 2013
- Immunosuppressive therapies in the management of acquired immune-mediated marrow failuresCurrent Opinion in Hematology, 2012
- Decreased Infection-Related Mortality and Improved Survival in Severe Aplastic Anemia in the Past Two DecadesClinical Infectious Diseases, 2011
- Th17 immune responses contribute to the pathophysiology of aplastic anemiaBlood, 2010
- Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cellsClinical and Experimental Immunology, 2009
- Over-expression of CXCR4 on mesenchymal stem cells augments myoangiogenesis in the infarcted myocardiumJournal of Molecular and Cellular Cardiology, 2008
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Tissue distribution and engraftment of human mesenchymal stem cells immortalized by human telomerase reverse transcriptase geneBiochemical and Biophysical Research Communications, 2005
- Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cellsTransplantation, 2003
- Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar developmentNature, 1998